Skip to main content

Table 2 Logistic regression analysis to identify factors associated with MRA prescription

From: Retrospective review of in hospital use of mineralocorticoid receptor antagonists for high risk patients following myocardial infarction

   Eligible   Ineligible  
   OR (95 % CI) Adjusted p-value OR (95 % CI) Adjusted p-value
Demographics Age 1.01 (0.98–1.03) 0.69 1.00 (0.98–1.02) 0.91
Female 0.97 (0.51–1.83) 0.92 2.22 (1.27–3.88) 0.01
Length of stay 1.01 (0.99–1.02) 0.33 1.01 (0.99–1.03) 0.17
Medical history Heart failure 1.66 (0.83–3.32) 0.15 2.38 (0.97–5.85) 0.06
Hypertension 0.99 (0.56–1.75) 0.97 1.24 (0.70–2.17) 0.46
Dyslipidemia 0.47 (0.26–0.85) 0.01 0.73 (0.41–1.29) 0.40
Diabetes 1.06 (0.61–1.83) 0.84 1.33 (0.69–2.56) 0.28
Smoking 1.84 (1.03–3.27) 0.04 1.39 (0.81–2.39) 0.23
MI 0.99 (0.50–1.95) 0.98 1.05 (0.54–2.03) 0.89
Clinical data SBP 0.99 (0.97–1.00) 0.16 1.00 (0.99–1.01) 0.58
Heart rate 1.01 (0.99–1.03) 0.17 0.99 (0.97–1.01) 0.40
LVEF 0.93 (0.90–0.97) 0.00 0.93 (0.90–0.96) 0.00
STEMI 1.44 (0.74–2.80) 0.28 1.62 (0.85–3.10) 0.15
Laboratory data Troponin T 1.02 (0.97–1.07) 0.39 1.05 (1.00–1.09) 0.05
Potassium 0.50 (0.23–1.08) 0.08 1.01 (0.56–1.79) 0.99
Estimated GFR 1.00 (0.99–1.01) 0.87 1.00 (0.99–1.01) 0.74
  1. Analysis of factors associated with increased rates of MRA prescription. CI, confidence interval; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; μg/L, micrograms per liter; μmol/L, micromole per liter; mmHg, millimeters mercury; mmol/L, millimoles per liter; OR, odds ratio; STEMI, ST elevation myocardial infarction; SBP, systolic blood pressure